. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2011 Nov 22;20(12):2551–2559. doi: 10.1158/1055-9965.EPI-11-0777

Table 2.

Cancer incidence rates, and rate ratios by HIV infection status

	HIV+		HIV−		Demographic-adjusted^b		Fully-adjusted^b

	n	rate^a	n	rate^a	RR (95% CI)	P	RR (95% CI)	P
Infection-related
Kaposi sarcoma	525	604	34	3	197.1 (139.2, 279.0)	<0.001	196.0 (138.1, 278.0)	<0.001
Non-Hodgkin lymphoma	241	269	193	17	15.9 (13.2, 19.3)	<0.001	15.4 (12.7, 18.7)	<0.001
Anal	86	96	18	2	60.9 (36.6, 101.4)	<0.001	55.7 (33.2, 93.4)	<0.001
Hodgkin lymphoma	52	58	32	3	19.8 (12.7, 31.0)	<0.001	18.7 (11.8, 29.5)	<0.001
Oral cavity/pharynx	26	29	183	16	1.9 (1.3, 2.9)	0.002	1.4 (0.9, 2.1)	0.14
Liver	24	27	110	10	2.6 (1.7, 4.0)	<0.001	1.8 (1.1, 2.8)	0.012
Infection-unrelated
Prostate	91	112	1,398	138	0.8 (0.6, 0.9)	0.012	0.8 (0.6, 0.9)	0.012
Lung	56	62	380	34	1.8 (1.4, 2.4)	<0.001	1.2 (0.9, 1.6)	0.15
Colorectal	35	39	459	41	0.9 (0.6, 1.3)	0.55	0.9 (0.6, 1.2)	0.34
Melanoma	34	38	266	24	1.8 (1.3, 2.6)	0.001	1.8 (1.3, 2.6)	0.001

RR, rate ratio

Crude incidence rate per 100,000 person-years

RR comparing cancer incidence in HIV-infected individuals with HIV-uninfected individuals (reference group) from Poisson regression models. Demographic-adjusted model included terms for HIV status, age, sex, race/ethnicity, calendar period, and KP region. Fully-adjusted model also included terms for smoking, overweight, and alcohol/drug abuse.